Sex-related effect on immunotherapy response: implications and opportunities
A partir d'une revue systématique de la littérature (8 essais randomisés), cette méta-analyse évalue, en fonction du sexe, les disparités dans la réponse à une immunothérapie à base d'anti-PD1 ou d'anti-PD-L1 dispensée en complément d'une chimiothérapie, chez des patients atteints d'un cancer du poumon
More than a century ago, astute clinicians noted that aggressive cancers occasionally regressed with significant co-infection, demonstrating the principle that an activated immune system might effectively attack cancer cells1. Since then, scientists have been striving to understand how the immune system defends against cancer—sometimes successfully, but often not. Investment in basic immunology research has begun to pay great dividends in the past decade as strategies to unleash the host immune system on tumors have ushered in a new class of drugs for cancer treatment. The age of ‘immunotherapy’ has transformed therapeutic approaches in oncology, increasing survival rates even in cancers that were previously difficult to treat, such as advanced melanoma, renal cancer, and lung cancer. (...)
Journal of the National Cancer Institute , éditorial, 2018